JPMorgan Chase & Co. decreased its holdings in shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) by 6.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,769,613 shares of the company’s stock after selling 126,347 shares during the quarter. JPMorgan Chase & Co.’s holdings in Biohaven Pharmaceutical were worth $91,081,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in BHVN. Flinton Capital Management LLC acquired a new position in Biohaven Pharmaceutical during the fourth quarter worth $42,000. Neuburgh Advisers LLC acquired a new position in Biohaven Pharmaceutical during the fourth quarter worth $52,000. Legal & General Group Plc boosted its holdings in Biohaven Pharmaceutical by 14.1% during the fourth quarter. Legal & General Group Plc now owns 5,284 shares of the company’s stock worth $196,000 after purchasing an additional 652 shares during the last quarter. AQR Capital Management LLC acquired a new position in Biohaven Pharmaceutical during the third quarter worth $218,000. Finally, Blueshift Asset Management LLC acquired a new position in Biohaven Pharmaceutical during the fourth quarter worth $306,000. Institutional investors and hedge funds own 84.77% of the company’s stock.

A number of brokerages have commented on BHVN. Morgan Stanley cut shares of Biohaven Pharmaceutical from an “overweight” rating to an “equal weight” rating and set a $49.13 price target for the company. in a research note on Tuesday, April 9th. They noted that the move was a valuation call. Goldman Sachs Group began coverage on shares of Biohaven Pharmaceutical in a research note on Monday, May 6th. They issued a “buy” rating and a $92.00 price target for the company. Cantor Fitzgerald reiterated a “buy” rating and issued a $75.00 price target on shares of Biohaven Pharmaceutical in a research note on Friday, February 8th. ValuEngine upgraded shares of Biohaven Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Finally, Needham & Company LLC increased their price target on shares of Biohaven Pharmaceutical to $70.00 and gave the company a “buy” rating in a research note on Wednesday, May 8th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $69.91.

In other news, Director Declan Doogan sold 5,351 shares of the stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $53.66, for a total value of $287,134.66. Following the transaction, the director now directly owns 373,913 shares of the company’s stock, valued at $20,064,171.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Vlad Coric sold 100,000 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $50.09, for a total transaction of $5,009,000.00. The disclosure for this sale can be found here. Insiders sold 383,778 shares of company stock worth $19,889,847 over the last three months. Insiders own 23.90% of the company’s stock.

Shares of BHVN stock opened at $61.83 on Friday. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of -10.05 and a beta of 0.60. Biohaven Pharmaceutical Holding Co Ltd has a one year low of $29.17 and a one year high of $65.64.

Biohaven Pharmaceutical (NYSE:BHVN) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($1.41) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.50) by $0.09. During the same quarter in the prior year, the business earned ($2.32) earnings per share. Equities research analysts expect that Biohaven Pharmaceutical Holding Co Ltd will post -6.54 EPS for the current year.

WARNING: “JPMorgan Chase & Co. Sells 126,347 Shares of Biohaven Pharmaceutical Holding Co Ltd (BHVN)” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2019/05/25/jpmorgan-chase-co-sells-126347-shares-of-biohaven-pharmaceutical-holding-co-ltd-bhvn.html.

Biohaven Pharmaceutical Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Featured Story: Forex

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.